Aadi Bioscience announced the appointment of Dave Lennon, Ph.D. as President and CEO. Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology and non-oncology mTOR-driven diseases. Dr. Lennon has also joined the Aadi Bioscience Board of Directors. In connection with Dr. Lennon’s appointment, Scott Giacobello, who served as Interim CEO and President since March 2023, will continue in his role as CFO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AADI:
